TTR is NOT a Treatment Chart—It's a Quality Metric for Anticoagulation Control
TTR (Time in Therapeutic Range) refers to the percentage of time a patient's INR values remain within the target therapeutic range (typically 2.0-3.0), calculated using the Rosendaal method of linear interpolation between consecutive INR measurements. 1 It is a validated performance measure of anticoagulation quality, not a treatment chart or documentation tool.
What TTR Actually Measures
TTR quantifies anticoagulation control by calculating the proportion of time patients spend with therapeutic INR values. The Rosendaal method interpolates linearly between two consecutive INR measurements to estimate daily INR values, though measurements >42 days apart are typically excluded due to uncertainty 1.
TTR is fundamentally different from simply counting the percentage of INR values in range—these metrics are highly correlated but not interchangeable and should not be used synonymously 1.
Clinical Significance and Target Values
For patients on warfarin, TTR should ideally be ≥70%, with a minimum acceptable threshold of 65%. 1 This target is critical because:
- TTR <65% significantly increases risks: stroke/systemic embolism (HR 2.55), all-cause mortality (HR 2.39), and major bleeding (HR 1.54) compared to TTR ≥65% 1
- Swedish registry data (n=40,449) showed dramatically lower annual rates when TTR ≥70%: thromboembolism (2.37% vs 4.41%), mortality (1.29% vs 4.35%), and major bleeding (1.61% vs 3.81%) 1
- Random "one-off" INR values provide minimal insight into actual anticoagulation control, as adverse outcomes occur even within therapeutic range 1
When TTR is Suboptimal
If TTR falls below 65-70%, implement these interventions or switch to a NOAC: 1
- Increase INR testing frequency
- Review and address medication adherence
- Identify factors affecting INR control (diet, drug interactions, comorbidities)
- Provide patient education and counseling
- Consider specialized anticoagulation clinic management
- Strongly consider switching to a NOAC (strong recommendation) 1
Common Pitfalls
The GARFIELD-AF registry revealed that only 41.1% of patients achieved TTR ≥65%, with only 51.4% of all INR values in therapeutic range 1. Geographic variation is substantial: Asia 16.7%, North America 45.9%, Europe 49.4% 1.
Critical factors affecting TTR include: patient-related aspects (age, sex, diet, ethnicity, comorbidities, polypharmacy, adherence) and healthcare system factors (management setting, clinic distance, monitoring frequency) 1.
The SAMe-TT₂R₂ score can identify patients likely to achieve good TTR: scores 0-2 predict good control, while scores >2 suggest need for intensive monitoring or preferential NOAC use 1.
Calculation Method Matters
Different TTR calculation methods yield significantly different values and should not be used interchangeably. 2 The Rosendaal method is the validated standard for clinical trials and quality measurement, though it requires more complex calculation than simple percentage of INRs in range 1.